Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of hMN14 (labetuzumab) in Colorectal or Breast Cancer
NCT00041652Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2000
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of labetuzumab in colorectal cancer (CRC), breast cancer, sponsored by Gilead Sciences. Started Feb 2000; status: completed.
02
Drugs
labetuzumab
03
Conditions
colorectal cancer (CRC)breast cancer
Beyond the preview
Go deeper on NCT00041652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041652.